Through the priority review and approval procedure, the SDA approved the listing of the first class innovative drug Riverutamide tablets (trade name: Arian) declared by Jiangsu Hengrui Pharmaceutical Co., Ltd. The drug is suitable for the treatment of metastatic sex hormone sensitive prostate cancer (mHSPC) with high tumor load. The introduction of this variety provides a new treatment option for patients with prostate cancer.
国家药监局附条件批准恒瑞医药瑞维鲁胺片上市
The State Drug Administration attached conditions to approve the listing of Hengrui Riverutamide tablets.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated